TG Therapeutics, Inc. (TGTX) DCF Valuation

TG Therapeutics, Inc. (TGTX) DCF Valuation
  • ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
  • ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
  • ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
  • ✓ Aucune Expertise N'Est Requise; Facile À Suivre

TG Therapeutics, Inc. (TGTX) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Looking to evaluate the intrinsic value of TG Therapeutics, Inc.? Our TGTX DCF Calculator integrates real-world data with extensive customization options, allowing you to refine your forecasts and enhance your investment strategies.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue .2 .2 6.7 2.8 233.7 316.4 428.4 580.1 785.6 1,063.7
Revenue Growth, % 0 0 4300.66 -58.36 8290.02 35.41 35.41 35.41 35.41 35.41
EBITDA -168.5 -272.7 -342.0 -187.6 26.1 -246.1 -333.2 -451.1 -610.9 -827.2
EBITDA, % -110856.58 -179393.42 -5112.41 -6737.13 11.17 -77.77 -77.77 -77.77 -77.77 -77.77
Depreciation .3 .4 .5 .5 .4 143.0 193.7 262.3 355.2 480.9
Depreciation, % 185.53 246.05 7.39 18.49 0.18103 45.21 45.21 45.21 45.21 45.21
EBIT -168.8 -273.1 -342.5 -188.1 25.7 -246.2 -333.3 -451.4 -611.2 -827.6
EBIT, % -111042.11 -179639.47 -5119.79 -6755.62 10.99 -77.8 -77.8 -77.8 -77.8 -77.8
Total Cash 140.4 605.4 350.3 174.1 217.5 312.0 422.5 572.1 774.7 1,049.0
Total Cash, percent .1 .4 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables .0 .0 1.4 .0 51.1
Account Receivables, % 0 0 20.77 0 21.87
Inventories .0 .0 -23.6 .0 39.8 -52.5 -71.1 -96.3 -130.3 -176.5
Inventories, % 0 0 -352.88 0 17.04 -16.59 -16.59 -16.59 -16.59 -16.59
Accounts Payable 30.0 37.0 .0 42.0 38.5 200.3 271.2 367.2 497.2 673.3
Accounts Payable, % 19763.82 24351.32 0 1508.76 16.46 63.29 63.29 63.29 63.29 63.29
Capital Expenditure -.1 -.4 -.4 .0 .0 -121.9 -165.1 -223.6 -302.7 -409.9
Capital Expenditure, % -86.18 -234.87 -5.99 -0.50269 0 -38.54 -38.54 -38.54 -38.54 -38.54
Tax Rate, % 2.99 2.99 2.99 2.99 2.99 2.99 2.99 2.99 2.99 2.99
EBITAT -175.1 -279.4 -349.8 -193.4 24.9 -244.7 -331.3 -448.7 -607.5 -822.6
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -144.9 -272.4 -364.5 -173.1 -69.1 54.6 -222.8 -301.7 -408.5 -553.2
WACC, % 14.72 14.72 14.72 14.72 14.72 14.72 14.72 14.72 14.72 14.72
PV UFCF
SUM PV UFCF -835.6
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) -564
Terminal Value -4,435
Present Terminal Value -2,232
Enterprise Value -3,067
Net Debt 18
Equity Value -3,085
Diluted Shares Outstanding, MM 149
Equity Value Per Share -20.77

What You Will Get

  • Real TG Therapeutics Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures.
  • Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
  • Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on TG Therapeutics’ fair value.
  • Versatile Excel Template: Tailored for quick edits, scenario testing, and detailed projections.
  • Time-Saving and Accurate: Skip building models from scratch while maintaining precision and flexibility.

Key Features

  • Customizable Clinical Parameters: Adjust essential metrics such as pipeline progress, market potential, and R&D expenditures.
  • Instant DCF Valuation: Quickly computes intrinsic value, NPV, and additional financial metrics.
  • High-Precision Analysis: Utilizes TG Therapeutics' actual financial data for accurate valuation results.
  • Effortless Scenario Testing: Evaluate various assumptions and assess different outcomes with ease.
  • Efficiency Booster: Avoid the complexities of creating intricate valuation models from the ground up.

How It Works

  • Download: Obtain the pre-built Excel file featuring TG Therapeutics, Inc. (TGTX) financial data.
  • Customize: Modify projections, including revenue growth, EBITDA %, and WACC.
  • Update Automatically: The intrinsic value and NPV calculations refresh in real-time.
  • Test Scenarios: Generate various projections and compare results instantly.
  • Make Decisions: Leverage the valuation outcomes to inform your investment approach.

Why Choose TG Therapeutics, Inc. (TGTX)?

  • Innovative Treatments: Focused on developing novel therapies for patients with hematologic malignancies and autoimmune diseases.
  • Strong Pipeline: A robust pipeline of drug candidates targeting unmet medical needs.
  • Expert Team: Led by experienced professionals with a proven track record in biotechnology.
  • Commitment to Patients: Dedicated to improving patient outcomes through cutting-edge research and development.
  • Proven Results: Backed by clinical data demonstrating the efficacy of our therapies.

Who Should Use TG Therapeutics, Inc. (TGTX)?

  • Investors: Gain insights into the potential of innovative therapies backed by robust research.
  • Healthcare Analysts: Streamline your analysis with detailed reports on drug development and market trends.
  • Pharmaceutical Consultants: Tailor materials for client engagements with up-to-date information on TG Therapeutics' pipeline.
  • Biotech Enthusiasts: Enhance your knowledge of the biotechnology sector through case studies and real-world applications.
  • Educators and Students: Utilize it as a resource for learning about drug development and market dynamics in pharmaceutical studies.

What the Template Contains

  • Pre-Filled DCF Model: TG Therapeutics’ financial data preloaded for immediate use.
  • WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
  • Financial Ratios: Evaluate TG Therapeutics’ profitability, leverage, and efficiency.
  • Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
  • Financial Statements: Annual and quarterly reports to support detailed analysis.
  • Interactive Dashboard: Easily visualize key valuation metrics and results.

No products were found matching.